ERBB2 and ductal breast carcinoma in situ: Vaccination of women with DCIS of the breast with dendritic cell vaccines presenting Her2-derived peptides led to the induction of immunity and provided some early evidence of antitumor effects, with a reduction in DCIS lesion seen in some patients at surgery (45).